Practice patterns among primary care physicians in benign prostatic hyperplasia and prostate cancer

Primary care physicians (PCPs) are increasingly managing prostate disorders, yet concerns about their education in this area persist. While urologists traditionally handle diagnosis and treatment, PCPs are now more involved. However, gaps remain in how PCPs apply clinical guidelines. Prior research has shown that PCPs commonly encounter patients with benign prostatic hyperplasia (BPH), but their adherence to evidence-based practices is unclear. The American Urological Association (AUA) symptom score is a tool for assessing BPH severity, but its use among PCPs is limited. This gap motivated a study to evaluate current PCP practice patterns. No prior work had resolved how often PCPs use standardized tools like the AUA score. The study aimed to clarify how PCPs screen for prostate cancer and manage BPH symptoms. It also sought to determine whether PCPs follow published clinical guidelines consistently.

This study aimed to assess how PCPs evaluate and treat benign prostatic hyperplasia (BPH) and screen for prostate cancer. The researchers sought to identify whether PCPs are using clinical guidelines effectively. They focused on PCP practice patterns in diagnosing and managing prostate disorders. The survey targeted PCPs attending scientific meetings in 1995. The goal was to determine how often PCPs apply the AUA symptom score and other diagnostic tools. The study also examined which therapies PCPs prefer for BPH treatment. It aimed to highlight discrepancies between recommended guidelines and actual practice. By analyzing survey responses, the researchers hoped to inform future educational efforts for PCPs.

The researchers conducted a survey with 10 questions distributed to 344 physicians at scientific meetings in 1995. The survey focused on PCP approaches to diagnosing and managing BPH and prostate cancer. It asked about the frequency of BPH symptoms in PCP patient populations. The questions included how often PCPs use the AUA symptom score and other diagnostic tools. The survey also collected data on PCP preferences for BPH treatments. It assessed whether PCPs perform digital rectal examinations (DRE) and request prostate-specific antigen (PSA) tests. The researchers analyzed responses to determine adherence to clinical guidelines. The data were used to compare PCP practices with published recommendations.

Eighty-nine percent of PCPs reported that up to 30% of their patients have symptomatic BPH. Sixty-one percent of PCPs are aware of the AUA symptom score, but only 38% use it in practice. The score is most commonly used for men with BPH symptoms (80%), men over 50 years (55%), and men with abnormal DRE findings (42%). Long-acting alpha blockers and watchful waiting are the most popular BPH treatments. Eighty-four percent of PCPs perform DREs in men over 50 years. Sixty-nine percent of PCPs request annual PSA tests for prostate cancer screening. These findings suggest limited use of clinical guidelines among PCPs. The survey highlights a gap between guideline recommendations and actual PCP practices.

The survey revealed that PCPs are increasingly managing prostate disorders but are not fully utilizing clinical guidelines. Eighty-nine percent of PCPs encounter patients with BPH symptoms, yet only 38% use the AUA symptom score. Long-acting alpha blockers and watchful waiting are preferred BPH treatments. Eighty-four percent of PCPs perform DREs in men over 50 years, and 69% request annual PSA tests. These findings suggest that PCPs are aware of but not consistently applying published guidelines. The authors propose that educational efforts should focus on improving PCP adherence to clinical recommendations. They suggest that increasing use of the AUA symptom score could improve diagnostic accuracy. The study highlights the need for better integration of guidelines into PCP practice patterns.